GENFIT: FDA Grants Key Designation to Its Candidate for Cirrhosis
GENFIT announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to G1090N (nitazoxanide), its experimental candidate for the treatment of acute decompensation in cirrhosis. This recognition of therapeutic potential paves the way for progression to phase 2 clinical trials.
The FDA has granted ODD to G1090N, GENFIT's most advanced program in the segment of acute decompensation in cirrhosis (ACLF). This designation recognizes the potential of the active substance to treat this rare disease characterized by rapid deterioration in patient condition, systemic inflammation, and high short-term mortality. The ODD follows recent phase 1 results demonstrating a favorable safety and tolerability profile in healthy volunteers, as well as data regarding anti-inflammatory activity observed in ex vivo models.
Regulatory and Financial Advantages of ODD
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The ODD designation provides GENFIT with FDA regulatory support, certain administrative fee reductions, and eligibility for seven years of market exclusivity in the United States for this indication if approved. These benefits create a solid foundation for advancing the program towards the initiation of a phase 2 clinical trial, scheduled for the second half of 2026.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 9.6M€
Risks mentioned
Dépendance aux partenaires pour le développement commercial.
Opportunities identified
Dynamique favorable des ventes d'Iqirvo renforçant les marges financières.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
